Rephonic
Artwork for The Uromigos

The Uromigos

The Uromigos
Prostate Cancer
Bladder Cancer
Kidney Cancer
Clinical Trials
Pembrolizumab
Immunotherapy
Renal Cell Carcinoma
Muscle-Invasive Bladder Cancer
Belzutifan
Non-Muscle Invasive Bladder Cancer
Overall Survival
Urothelial Cancer
Enzalutamide
Abiraterone
Adjuvant Therapy
PARP Inhibitors
Tar-200
Cabozantinib
Chemotherapy
Biomarkers

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

PublishesDailyEpisodes501Founded7 years ago
Number of ListenersCategories
MedicineHealth & Fitness

Listen to this Podcast

Artwork for The Uromigos

Latest Episodes

Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!

Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!

Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.

Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

GU Cast | Urology Podcast
GU Cast | Urology PodcastProfessor Declan Murphy & Dr Renu Eapen
Two Onc Docs
Two Onc DocsSam and Karine
Plenary Session
Plenary SessionVinay Prasad, MD MPH
Acquired
AcquiredBen Gilbert and David Rosenthal

Recent Guests

Danny Heng
Oncologist presenting the LITESPARK-011 final analysis
Episode: Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival
Chris Sweeney
Prostate cancer researcher and investigator in cooperative group clinical trials
ANZUP Cancer Trials Group
Episode: Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer
Michiel Van Der Heijden
Episode: Episode 526: ESMO 2026 - The VOLGA trial in MIBC
Karim Fizazi
Medical oncologist discussing prostate cancer clinical trials and ESMO 2026 presentations
Episode: Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281
Ben Garmezy
Oncologist at Sarah Cannon who discusses phase 1 data for JNJ-6143
Sarah Cannon
Episode: Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC
Jon Chatzkel
Researcher presenting ctDNA findings from the KEYNOTE 905 trial
Episode: Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC
Anders Ullen
Researcher at the Karolinska Institute who presented an analysis of KEYNOTE-905
Karolinska Institute
Episode: Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
Rob Jones
Episode: Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
Silke Gillison
Colleague and expert guest discussing GU cancers
Episode: Episode 520: ESMO 2026 Preview

Hosts

Tom Powles
Co-host of The Uromigos; Professor of Genitourinary Oncology; Director of Barts Cancer Centre; affiliated with Queen Mary University of London and Barts Cancer Centre
Brian Rini
Host of The Uromigos; Ingram Professor of Medicine (Hematology/Oncology); affiliated with Vanderbilt-Ingram Cancer Center

Reviews

4.8 out of 5 stars from 176 ratings
  • Amazing information!

    I am no medical doctor but a PhD researcher in big pharma. Love the details and makes you keep updated with the latest medical findings. Will help if doctors can elaborate when they talk about treatment if it’s 1L or 2L etc.

    Apple Podcasts
    5
    gERDorNerd
    United States16 days ago
  • Excellent resource for patients anddocs

    The Uromigos keep patients and doctors informed with the very latest studies and research in urogenital cancer. I appreciate their hopeful, upbeat and revealing interviews with cutting edge researchers.

    Apple Podcasts
    5
    Tea Green
    United Statesa year ago
  • Informative podcast

    This podcast is a one-stop shop for all things GU oncology. The information is balanced, up to date and relevant for anyone in this field

    Apple Podcasts
    5
    F93111111
    United Kingdom2 years ago
  • Great for staying up on GU oncology

    Drs. Powles and Rini are some of the most eminent current leaders in GU oncology. In this podcast, they discuss recent key studies in the field and really break down the key questions clinicians and patients want to know — are they clinically significant, will they change practice, and what are the next steps? Also, there are a lot of cheesy jokes which this humble listener somehow enjoys.

    Apple Podcasts
    5
    Attentive listener 12345
    United States3 years ago
  • Topical and interesting

    Great discussion of topical issues within the urology space from a engaging, experienced and knowledgeable group of oncologists.

    Apple Podcasts
    5
    Antman1805
    Australia3 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Engaging hosts balance data critique with approachable humor, making dense topics accessible.
Guests are subject-matter experts who translate complex trials for clinicians and patients.
Shows high-quality, up-to-date GU oncology data explained clearly.
Great resource for trainees and practicing oncologists alike.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
Q: For future trials, do we need to stratify patients by circulating tumor DNA burden?
The speakers discuss its strong prognostic value but say there is not yet enough evidence to require stratification. A practical, validated test could make it a reasonable factor to consider.
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
Q: Does the similar increase in pathological complete response across the trials mean it is not a useful marker?
Rob Jones says pathological complete response may indicate treatment activity, but it is not a proven surrogate for survival and cannot establish clinical benefit on its own. Similar increases across the trials suggest that other factors may explain their different survival results.
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
Q: If a patient had severe neuropathy and could not receive enfortumab vedotin, do these data support giving pembrolizumab monotherapy?
Ullen says the small, ad hoc analysis is descriptive rather than sufficient evidence to recommend monotherapy for patients ineligible for enfortumab vedotin. Powles says he sees no clear role for perioperative pembrolizumab alone in this setting.
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
Q: Do these data tell us anything about the adjuvant phase in terms of necessity, toxicity, benefit, or risk?
The speakers say the analysis cannot determine the value of the adjuvant phase or how many cycles are needed, because treatment exposure varied and the arms included combined neoadjuvant and adjuvant regimens.
Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC
Q: Would you use pre-surgery ctDNA clearance or lack thereof to change management, and how might providers use it to guide local therapy or treatment?
The speakers say the findings are not ready to guide decisions such as avoiding cystectomy or stopping therapy. They see potential for future clinical trials to test ctDNA-guided treatment changes, while emphasizing that such decisions require further evidence.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The Uromigos

What is The Uromigos about and what kind of topics does it cover?

The show consistently provides expert-led analysis of GU cancers, with a strong focus on trial design, biomarker-driven strategies, and real-world applicability of high-stakes data. Conversations span prostate, bladder, kidney cancers and emerging modalities like targeted ADCs, radioligand therapy, and AI-enabled evidence. Hosts guide rigorous debates about trial endpoints, regulatory implications, and how new data could shift practice, while maintaining a personable, accessible tone that blends humor with clinical insight. Noteworthy is the blend of frontline clinicians, translational scientists, regulatory voices, and senior researchers, which gives listeners a practical sense of what data means for patient care and decision-making in rea... more

Where can I find podcast stats for The Uromigos?

Rephonic provides a wide range of podcast stats for The Uromigos. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The Uromigos and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The Uromigos get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for The Uromigos, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The Uromigos?

Rephonic provides comprehensive predictive audience data for The Uromigos, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The Uromigos have?

To see how many followers or subscribers The Uromigos has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The Uromigos?

These podcasts share a similar audience with The Uromigos:

1. GU Cast | Urology Podcast
2. Two Onc Docs
3. Prostate Cancer Update
4. Plenary Session
5. Acquired

How many episodes of The Uromigos are there?

The Uromigos launched 7 years ago and published 501 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The Uromigos?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The Uromigos?

Rephonic pulls ratings and reviews for The Uromigos from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The Uromigos?

Rephonic provides full transcripts for episodes of The Uromigos. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The Uromigos?

Recent guests on The Uromigos include:

1. Danny Heng
2. Chris Sweeney
3. Michiel Van Der Heijden
4. Karim Fizazi
5. Ben Garmezy
6. Jon Chatzkel
7. Anders Ullen
8. Rob Jones

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days